AbstractObjective To preliminarily evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) in the treatment of inoperable stage ⅣA thymoma. Methods A retrospective analysis of 15 patients with inoperable stage ⅣA thymoma receiving IMRT from January 2010 to December 2017 was performed. Among them, 9 patients were male and 6 female,aged 31-83 years with a medianof 59 years. The dose of radiotherapy was 50Gy/60Gy/70Gy/15-20 fractions for PTV/CTV/GTV. The short-term efficacy,overall survival rate and adverse reactions were analyzed. Results The follow-up rate was 100%. The median follow-up time was 48 months. The short-term partial remission rate was 93%(14/15). The 1-,3-and 5-year overall survival rates were 100%,75% and 75%,respectively. One patient presented with grade 3 hematological reaction. Four patients died of tumors.Conclusion Preliminary findings demonstrate that IMRT is an efficacious and safe treatment of stageⅣA thymoma, which can be applied for patients with unresectable thymoma.
Corresponding Authors:
Wang Yingjie,Email:wangyj9999@163.com
Cite this article:
Chang Dongshu,Li Ping,Li Jing et al. Preliminary analysis of efficacy and safety of intensity-modulated radiotherapy for stage ⅣA thymoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 184-186.
Chang Dongshu,Li Ping,Li Jing et al. Preliminary analysis of efficacy and safety of intensity-modulated radiotherapy for stage ⅣA thymoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 184-186.
[1] 方文涛,傅剑华,沈毅,等.胸腺肿瘤的诊疗:基于中国胸腺肿瘤协作组多中心回顾性研究的共识[J]. 中国肺癌杂志,2016,19(7):414-417. DOI:10.3779/j.issn.1009-3419.2016.07.02.
Fang WT,Fu JH,Shen Y,et al. Management of thymic tumors consensus based on the Chinese alliance for resesrch in thymomas multi-institutional retrospective studies[J]. Chin J Lung Cancer,2016,19(7):414-417. DOI:10.3779/j.issn.1009-3419.2016.07.02.
[2] Masaoka A. Staging system of thymoma[J]. J Thorac Oncol,2010,5(10 Suppl 4):S304-312.
[3] Tingyi X,Hongqi L,Yingjie W,et al. Promising clinical outcome of steretactic body radiation therapy for patients withimoperable stage Ⅰ/Ⅱ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2006,66(1):117-125. DOI:10.1016/j.ijrobp.2006.04.013.
[4] 常冬姝,李平,王颖杰. 全身γ刀治疗局限期胰腺癌临床结果分析[J]. 中华放射肿瘤学杂志,2009,18(6):470-473. DOI:10.3760/cma.j.issn.1004-4221.2009.06.470.
Chang DS,Li P,Wang YJ. Bureau of whole-body gamma knife treatment of pancreatic cancer clinical results within a time limit[J]. Chin J Radiat Oncol,2009,18(6):470-473.DOI:10.3760/cma.j.issn.1004-4221.2009.06.470.
[5] 常冬姝,夏廷毅. 不能手术肾癌及肾盂输尿管癌放疗效果分析[J]. 中华放射肿瘤学杂志,2018,27(3):277-280. DOI:10.3760/cam.j.issn.1004-4221.2018.03.010.
Chang DS,Xia TY. Outcome of radiotherapy for unresectable renal cell carcinoma and renal pelvis and ureter cancer[J]. Chin J Radiat Oncol,2018,27(3):277-280. DOI:10.3760/cam.j.issn.1004-4221.2018.03.010.
[6] Vogel J,Berman AT,Lin LY,et al. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma:early response and toxicity assessment[J]. Radiother Oncol,2016,118(3):504-509. DOI:10.1016/j.radonc.2016.02.003.
[7] 马绍峰,伍炜,应克明,等. 立体定向放疗胸腺瘤17例[J]. 蚌埠医学院学报,2007,32(1):95-96. DOI:10.3969/j.issn.1000-2200.2007.01.044.
Ma SF,Wu W,Ying KM,et al. Stereotactic radiotherapy for 17 cases of thymoma[J]. J Bengbu Med College,2007,32(1):95-96. DOI:10.3969/j.issn.1000-2200.2007.01.044.
[8] 孙建刚,陈维艳,江启安. 立体定向放疗38例胸腺瘤近期疗效报告[J]. 肿瘤研究与临床,2002,14(1):49. DOI:10.3760/cma.j.issn.1006-9801.2002.01.025.
[9] 王常禄,吕长兴,王家明,等. 无法手术切除的30例胸腺瘤行放疗或放疗联合化疗的疗效分析[J]. 肿瘤,2009,29(4):370-373. DOI:10.3781/j.issn.1000-7431.2009.04.017.
[10] Tamiya A,Matsumura A,Tsuji T,et al. A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma[J]. Anticancer Res,2014,34(4):2023-2027.
2020, Vol. 29 
